Korro Bio, Inc. Payments to Acquire Debt Securities, Available-for-sale
Korro Bio, Inc. (KRRO) reported Payments to Acquire Debt Securities, Available-for-sale of $26.34 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2021-03-29
- Korro Bio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2019-12-31 was $13.80M.
- Korro Bio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2019-09-30 was $125.99M.
- Korro Bio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2019-06-30 was $107.95M.
- Korro Bio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2019-03-31 was $34.88M.
- Korro Bio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2020 was $26.34M, a 90.68% decline from fiscal 2019.
- Korro Bio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2019 was $282.62M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $26.34M 10-K · filed 2021-03-29 | ||||
| 2019-12-31 | $13.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $139.79M derived: sum of 2 quarters · filed 2021-03-29 | $247.74M derived: sum of 3 quarters · filed 2021-03-29 | $282.62M 10-K · filed 2021-03-29 | $265.42M 10-K · filed 2020-03-26 |
| 2019-09-30 | $125.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $233.94M derived: sum of 2 quarters · filed 2020-11-16 | $268.82M 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $107.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $142.83M 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $34.88M 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |